AstraZeneca today announced that it has completed the licensing agreement (https://www.astrazeneca.com/media-centre/press -releases/2016/astrazeneca-enters-into-us-licensing-agreement-with-ironwood -pharmaceuticals-for-lesinurad-26042016.html) with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout. The fixed-dose combination will be submitted for regulatory review in the second half of 2016. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Neil Burrows UK/Global +44 7824 350541 Vanessa Rhodes UK/Global +44 7880 400690 Karen Birmingham UK/Global +44 7818 524012 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Enquiries UK Thomas Kudsk Larsen +44 7818 524185 Nick Stone RIA +44 7717 618834 Henry Wheeler Oncology +44 7788 354619 Craig Marks Finance +44 7881 615764 Christer Gruvris ING +44 7827 836825 US Lindsey Trickett CVMD +1 240 543 7970 Mitchell Chan Oncology +1 240 477 3771 Dial / Toll-Free +1 866 381 7277 Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal 3 June 2016 -ENDS-
ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD
| Quelle: AstraZeneca PLC
Anhänge
